<DOC>
	<DOCNO>NCT02621957</DOCNO>
	<brief_summary>This study ass pharmacokinetics ( PK ) single dose pravastatin without concomitant GDC-0810 administration healthy female subject non-childbearing potential . During Period 1 ( Day -1 Day 4 ) PK parameter pravastatin determined absence GDC-0810 . During Period 2 ( Days 5-28 ) PK parameter pravastatin determine presence GDC-0810 .</brief_summary>
	<brief_title>Effect GDC-0810 Pharmacokinetics Pravastatin Healthy Female Subjects Non-Childbearing Potential</brief_title>
	<detailed_description />
	<mesh_term>Pravastatin</mesh_term>
	<criteria>Female subject 18 65 year age , inclusive . Female subject nonchildbearing potential include nonpregnant , nonlactating , either postmenopausal surgically sterile least 45 day post procedure . Within BMI range 18.5 &lt; /= 29.9 kg/m^2 , inclusive . In good health , determine clinically significant finding medical history , physical examination , 12lead electrocardiogram ( ECG ) , vital sign , clinical laboratory evaluation . Receive explanation mandatory pharmacogenomic ( PgX ) component study . Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder . Previous history adverse reaction statin . Participation investigational study drug trial receipt investigational study drug occur within 30 day 5 halflives , whichever longer , prior Checkin ( Day 1 ) Period 1 . Use systemic hormone replacement therapy within 1 year prior Checkin ( Day 1 ) . History use tamoxifen , aromatase inhibitor endocrine agent treatment breast cancer . Female subject pregnant lactating , breast feeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>